cardiology MCQ (SBA): ACC Expert Consensus Pathway (2022): Nonstatin Therapies for LDL-C Lowering

Instant feedback + full explanation. One question, done properly.

MediumfibratesACC Expert Consensus Pathway (2022): Nonstatin Therapies for LDL-C Loweringcardiology

A 72-year-old with dyslipidemia on maximal statin and ezetimibe has LDL-C 92 mg/dL after PCI. What is the next escalation per ACC consensus if very-high-risk?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.